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(severe NOH; 0.2–3.0). Using utilities from the literature, net
health beneﬁts were calculated for 5%, 10%, 15% and 20%
10-year background risks of cardiovascular events. RESULTS:
The estimated net health beneﬁts for progression to legal blind-
ness for both medications versus UC were positive and declined
with increasing baseline risk of cardiovascular events. The abso-
lute decline in beneﬁt was greater for ranibizumab than for
pegaptanib (0.67 vs 0.10 quality adjusted life years, respectively)
when the background risk of APTC events increased from 5% to
20%. CONCLUSION: As it incorporates both intended and
unintended effects, estimating net health beneﬁts may be more
informative than combining estimates of efﬁcacy with an
unstructured incorporation of adverse event rates. While both
pegaptanib and ranibizumab show positive net health beneﬁts for
AMD, the risk of cardiovascular events is an important consid-
eration when selecting treatment.
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OBJECTIVES: The purpose of the study is to compare results of
Conjoint analysis from 3 studies in ophthalmology with other
standard measures of QoL. METHODS: The 3 choice based
conjoint (CBC) studies included two in people with glaucoma
(N = 109, N = 74) in which the same attributes but a different
presentation order was used, and one in people with Age Related
Macular Degeneration (N = 126). Other QoL measures included
time trade off, VF-14, NEI-VFQ 25 and EuroQoL. RESULTS: In
all 3 studies the top two attributes were ‘reading’ and ‘getting
about outside’. For the two glaucoma studies, lower ranked
attributes changed position under different presentational order.
A simpler version of the conjoint task using only 3 of the 5
attributes was given to selected AMD patients with poor vision
and showed the same rank order of attributes as in the 5 attribute
task. There were very low correlations between individual con-
joint measures and other Qol measures. (e.g. only 2 out of 65
intercorrelations between NEI and conjoint scores reached
p < 0.05). In time trade off, only around 50% of AMD patients
and 20% of glaucoma patients were prepared to trade any
remaining years and in both cases it was those with poorer vision
(Snellen acuity > 6/12) who were willing to trade (p < 0.01). All
studies showed two subgroups of patients with priorities in
‘reading’ and ‘getting about outdoors’. Shifts of attribute prefer-
ence for changing levels of visual acuity and visual ﬁeld occurred
but not changes in rank order. CONCLUSION: Results from 3
studies (2 glaucoma, 1 ARMD) show little relationship between
Conjoint QoL measures and TTO, VF-14, NEI-VFQ 25 and
EuroQoL suggesting they are assessing different aspects of QoL.
EYE—Patient Reported Outcomes
PEY13
TIMETO DISCONTINUATION OF GLAUCOMA MEDICINES
PRESCRIBED SUBSEQUENTTO INITIALTHERAPY
Montgomery DMI1,Witchalls A1, Pleil A2
1Glasgow Royal Inﬁrmary, Glasgow, UK, 2Pﬁzer Inc, San Diego, CA,
USA
OBJECTIVES: To determine the time to discontinuation of dif-
ferent glaucoma medications prescribed subsequent to initial ﬁrst
line therapy in the management of ocular hypertension, primary
open angle glaucoma or normal tension glaucoma. METHODS:
A computerized database at the Glaucoma Clinic of Glasgow
Royal Inﬁrmary currently contains complete treatment histories
of 890 patients with ocular hypertension, primary open angle
glaucoma and normal tension glaucoma. In 1999 the database
was populated with retrospective data abstracted from medical
records dating from as early as 1981, with particular attention
paid to the timing and reasons for treatment changes. Since then
the database has been updated prospectively for all patients
treated medically for these conditions. Treatment discontinua-
tions occur due to efﬁcacy failure, side effects, and/or by patient
choice. Kaplan-Meier analysis was used to describe the time to
therapy discontinuation across a range of second-line glaucoma
treatments without controlling for reason. The number and per-
centages of discrete treatment episodes with each drug exceeding
12, 36, and 60 months duration were determined. Each subject
may have contributed more than one episode over the observa-
tion period. RESULTS: Overall, persistency on Xalacom was
higher than all other drugs at all three time points with 82.7%;
67.6%; and 64.2% (n = 363) of the episodes exceeding 12, 36,
and 60 months in duration respectively. Corresponding persis-
tency rates for other therapies were: Cosopt (the only other ﬁxed
combination in the study) 66.5%; 55.6%; 49.0% (n = 495);
Alphagan 47.6%; 24.0%; 15.0% (n = 601); Azopt 76.4%;
57.9%; 52.5% (n = 304); Betoptic 51.2%; 25.8%; 13.4%
(n = 117); Lumigan 74.0%; 53.6%; N/A (n = 108); Timoptol
0.5% LA 51.2%; 19.9%; 6.6% (n = 123); Travatan 55.5%;
50.1%; 50.1% (n = 69); Trusopt 53.7%; 26.8%; 12.2%
(n = 281); Xalatan 76.8%; 54.6%; 47.5% (n = 944). CONCLU-
SION: Persistency rates at 12, 36, and 60 months were higher for
Xalacom than other medications when used as subsequent
therapy.
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OBJECTIVES: To evaluate the persistence degree (period of time
with continuous medication intake) of glaucoma patients with
monotherapy prostaglandins treatment (latanoprost, bimato-
prost, travoprost). METHODS: An interim analysis of an obser-
vational and retrospective study was performed; 99 patients
(from 4 ophthalmology services) were included and followed
through a period of 24 months, studying the moment in which
patients drop out of treatment. Needed parameters were
obtained from medical records. A descriptive analysis, a Kaplan-
Meier survival analysis and a Cox regression model were carried
out, in order to determine: ﬁrstly, the antiglaucoma agent that is
related with a higher persistence degree; and secondly, to detect
those variables that involve a signiﬁcant variation on the persis-
tence of these patients. RESULTS: In both the descriptive analysis
and the survival curves, latanoprost was associated with a higher
persistence degree in the glaucoma treatment: 81% vs. 43.9% for
bimatoprost and travoprost (p < 0.0003). The persistence degree
was signiﬁcantly inﬂuenced by the following variables: the anti-
glaucoma agent used as monotherapy, with a 3-times higher
hazard of treatment withdrawal during the follow-up period due
to receiving a travoprost or bimatoprost treatment instead of a
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